SABCS24 | Should tamoxifen be considered for DCIS patients after breast conserving surgery?

The combined dataset of two clinical trials shows tamoxifen significantly decreases ipsilateral breast recurrence in “good risk” ductal carcinoma in situ patients who forgo radiation Results from the combined databases of the NRG/RTOG 9804 and ECOG-ACRIN E5194 trials, presented at the San Antonio Breast Cancer Symposium (10–14 December 2024, TX, USA), demonstrated that patients with “good risk” ductal carcinoma in situ (DCIS) who underwent breast conserving surgery and did not receive radiotherapy, may benefit from tamoxifen for reducing recurrence risk. Patients were defined as “good risk” if they had grade 1 or 2 tumors less than 2.5cm in diameter that...